Head and Neck Cancer — Trials, FDA Actions & Pivotal Research
18 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Head and Neck Cancer.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Head and Neck Cancer trials
Recruiting trials by city
Cities where Head and Neck Cancer trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Results postedPembrolizumab with Metformin Shows Improved PFS, OS in Head and Neck Cancer· May 8, 2026· drug: Pembrolizumab
- Results postedNivolumab Adjuvant Therapy Shows 71.4% Disease-Free Survival in Head and Neck…· May 6, 2026· drug: Nivolumab
- Results postedPembrolizumab with L-NMMA Phase 1b Trial Identifies 20 mg/kg MTD· Apr 9, 2026· drug: Pembrolizumab
- Results postedPembrolizumab + IO102-IO103 Trial Posts ORR, PFS Data for NSCLC, SCCHN, mUBC· Apr 8, 2026· drug: Pembrolizumab
- Results postedPembrolizumab Combination Trial for Solid Tumors Reports DLTs at High Dose· Mar 27, 2026· drug: Pembrolizumab
- Results postedPembrolizumab Plus Radiotherapy Shows Improved Response in Metastatic HNSCC· Mar 12, 2026· drug: Pembrolizumab
- Results postedHead and Neck Cancer: INRT Study Posts Recurrence and QoL Results· Feb 19, 2026
- Results postedPembrolizumab + Tadalafil Phase 2 Trial Shows Safety, PFS Data in Head and…· Feb 12, 2026· drug: Pembrolizumab
- Results postedPembrolizumab + Danvatirsen HNSCC Trial Results Posted, Study Terminated· Jan 30, 2026· drug: Pembrolizumab
- Results postedPembrolizumab Combination Shows Responses in Refractory Advanced Cancers· Jan 29, 2026· drug: Pembrolizumab
- Results postedNew Cone-beam CT Scanner for Radiotherapy: Image Quality Results Posted· Jan 6, 2026
2025
- Results postedHPV-Associated Oropharynx Cancer: De-intensified Radiotherapy MTD Determined· Dec 15, 2025
- Results postedPembrolizumab/Magrolimab Combo Shows Similar PFS to Pembrolizumab Alone in HNSCC· Nov 19, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Combination Shows Responses in NSCLC, Head and Neck Cancers· Oct 22, 2025· drug: Pembrolizumab
- Results postedHead and Neck Cancer: Maskless Immobilization Device Shows High Accuracy· Oct 15, 2025
- Results postedHead and Neck Cancer: Oral Care Protocol Shows Minimal Impact on Mucositis· Sep 26, 2025
- Results postedPembrolizumab/Enoblituzumab Combination Reports Low DLTs in Refractory Cancers· Aug 11, 2025· drug: Pembrolizumab
- Primary completionHead and Neck Cancer Trial Optimizing Radiotherapy Reaches Primary Completion· May 31, 2025